Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma ( (TNXP) ) has shared an announcement.
On March 31, 2026, Tonix Pharmaceuticals announced program updates for TNX-4800, its monoclonal antibody candidate for protection against Lyme disease, highlighting that Phase 1 data were presented on March 30, 2026, at the World Vaccine Congress Washington 2026. Based on pharmacokinetic results, the company selected a fixed 350 mg subcutaneous dose for further testing.
Tonix outlined plans for a randomized, double-blind, placebo-controlled adaptive Phase 2 field study, expected to start in the first half of 2027 pending FDA clearance, to test whether a single 350 mg dose can prevent first occurrences of confirmed Lyme disease over four and six months in adolescents and adults aged 16 to 65 in U.S. Lyme-endemic areas. The company expects GMP investigational product to be ready for clinical use in early 2027 and, if needed and cleared by regulators, may pursue a controlled human infection model study in 2028, signaling an aggressive development trajectory for TNX-4800 in the Lyme prevention market.
The most recent analyst rating on (TNXP) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
The score is held down primarily by weak fundamentals—very large operating losses and persistent negative operating/free cash flow—despite improving revenue and gross margin and a low-debt balance sheet. Technicals remain bearish with the stock below key moving averages, while recent positive clinical and listing-related corporate events provide some offset but are not yet reflected in financial self-sufficiency.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company developing therapeutics, including monoclonal antibody candidates, targeting infectious diseases such as Lyme disease. Its pipeline includes TNX-4800, designed as a single-dose, subcutaneous prophylactic treatment for individuals in Lyme-endemic regions of the U.S.
Average Trading Volume: 413,700
Technical Sentiment Signal: Strong Sell
Current Market Cap: $161.3M
See more insights into TNXP stock on TipRanks’ Stock Analysis page.